Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: A multicenter, randomized control trial in southwest China

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 657-664

  Zhang, Xi ^a   Li, Yunlong ^a   Zhang, Yanqi ^a   Chen, Xinghua ^a   Zhang, Cheng ^a   Gao, Li ^a   Kong, Peiyan ^a   Liu, Yao ^a   Wen, Qin ^a   Zeng, Yunjing ^a   Wang, Qingyu ^a   Su, Yi ^b   Wang, Chunsen ^c   Wang, Sanbin ^d   Yuan, Zhong ^e   Gao, Lei ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d Department of Hematology General Hospital of Kunming Military Region of PLA   (China)

^e ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Aclarubicin; Acute myeloid leukemia; Etoposide; Hematopoietic stem cell transplantation; Recombinant human granulocyte colony stimulating factor; Refractory; Relapsed

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CHINA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT DURATION;

ACLARUBICIN; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877037795     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.005     Document Type: Article

References (33)

1. Pui C., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535-1548.
2. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163.
3. Renneville A., Roumier C., Biggio V., et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-931.
4. Faderl S., Verstovsek S., Cortes J., et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006, 108:45-51.
5. Mikkael S., Richard S. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002, 14:24-30.
6. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010, 115:453-474.
7. Nathan P.C., Sung L., Crump M., et al. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004, 96:38-45.
8. Löwenberg B., Putten W., Theobald M., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
9. Knapper S., Burnett A.K., Littlewood T., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006, 108:3262-3270.
10. Büchner T., Hiddemann W., Berdel W.E., et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003, 21:4496-4504.
11. Yamada K., Furusawa S., Saito K., et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995, 9:10-14.
12. Bai A., Kojima H., Hori M., et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 1999, 27:259-265.
13. Hande K.R. Etoposide: four decades of development of atopoisomerase II inhibitor. Eur J Cancer 1998, 34:1514-1521.
14. Kaufmann S.H., Karp J.E., Jones R.J., et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994, 83:517-530.
15. Rowe J.M., Chang A., Benne J.M. Aclacinomycin A and etoposide (VP.-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood 1988, 71:992-996.
16. Greenberg P.L., Lee S.J., Advani R., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004, 22:1078-1086.
17. Röllig C., Bornhäuser M., Thiede C., et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European Leukemia Net Recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011, 29:2758-2765.
18. Löenberg B., Putten W., Theobald M., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
19. Tse E., Leung A., Sim J., et al. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol 2011, 90:1277-1281.
20. Shipley J.L., Butera J.N. Acute myelogenous leukemia. Exp Hematol 2009, 37:649-658.
21. ®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol 2009, 88:151-158.
22. Zhang W., Wang F., Chen Y., et al. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol 2008, 83:185-188.
23. Li J.M., Shen Y., Wu D.P., et al. Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 2005, 82:48-54.
24. Wei G., Ni W., Chiao J., et al. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 2011, 4:46-58.
25. Quennet V., Beucher A., Barton O., et al. CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1. Nucleic Acids Res 2011, 39:2144-2152.
26. Greco F.A. Future directions for etoposide therapy. Cancer 1991, 67:315-318.
27. Towatari M., Ito Y., Morishita Y., et al. Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells. Cancer Res 1990, 50:7198-7202.
28. Swift L.P., Rephaeli A., Nudelman A., et al. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006, 66:4863-4871.
29. Amadori S., Suciu S., Jehn U., et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005, 106:27-34.
30. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
31. Hofmann W.K., Heil G., Zander C., et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 2004, 83:498-503.
32. Agura E., Cooper B., Holmes H., et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011, 16:197-206.
33. Larson S.M., Campbell N.P., Huo D., et al. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma 2012, 53:445-450.